Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 2
2006 1
2009 3
2010 1
2011 3
2012 8
2013 7
2014 2
2015 3
2016 2
2017 7
2018 4
2019 2
2020 3
2021 3
2022 5
2023 13
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Editorial: Molecular Mechanisms of Multiple Myeloma.
Gozzetti A, Kok CH, Li CF. Gozzetti A, et al. Among authors: kok ch. Front Oncol. 2022 Mar 10;12:870123. doi: 10.3389/fonc.2022.870123. eCollection 2022. Front Oncol. 2022. PMID: 35359371 Free PMC article. No abstract available.
Editorial: Advances in the treatment of chronic myeloid leukemia.
Eşkazan AE, Kok CH, Yeung D, Dalal J, Tiribelli M. Eşkazan AE, et al. Among authors: kok ch. Front Oncol. 2023 Mar 9;13:1166588. doi: 10.3389/fonc.2023.1166588. eCollection 2023. Front Oncol. 2023. PMID: 36969003 Free PMC article. No abstract available.
Update on cardiac imaging: A critical analysis.
Shah H, Alim S, Akther S, Irfan M, Rahmatova J, Arshad A, Kok CHP, Zahra SA. Shah H, et al. Among authors: kok chp. Clin Investig Arterioscler. 2024 Apr 8:S0214-9168(24)00022-6. doi: 10.1016/j.arteri.2024.03.001. Online ahead of print. Clin Investig Arterioscler. 2024. PMID: 38594128 Review. English, Spanish.
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.
Shah MV, Tran ENH, Shah S, Chhetri R, Baranwal A, Ladon D, Shultz C, Al-Kali A, Brown AL, Chen D, Scott HS, Greipp P, Thomas D, Alkhateeb HB, Singhal D, Gangat N, Kumar S, Patnaik MM, Hahn CN, Kok CH, Tefferi A, Hiwase DK. Shah MV, et al. Among authors: kok ch. Blood Cancer J. 2023 Apr 11;13(1):51. doi: 10.1038/s41408-023-00821-x. Blood Cancer J. 2023. PMID: 37041128 Free PMC article.
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention.
Shanmuganathan N, Wadham C, Shahrin N, Feng J, Thomson D, Wang P, Saunders V, Kok CH, King RM, Kenyon RR, Lin M, Pagani IS, Ross DM, Yong ASM, Grigg AP, Mills AK, Schwarer AP, Braley J, Altamura H, Yeung DT, Scott HS, Schreiber AW, Hughes TP, Branford S. Shanmuganathan N, et al. Among authors: kok ch. Haematologica. 2023 Sep 1;108(9):2380-2395. doi: 10.3324/haematol.2022.282184. Haematologica. 2023. PMID: 36951160 Free PMC article.
66 results